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Chronic obstructive pulmonary disease (COPD), the fourth leading cause of death world-
wide, is characterized by irreversible airflow limitation based on obstructive bronchiolitis, 
emphysema, and chronic pulmonary inflammation. Inhaled toxic gases and particles, e.g., 
cigarette smoke, are major etiologic factors for COPD, while the pathogenesis of the dis-
ease is only partially understood. Over the past decade, an increasing body of evidence 
has been accumulated for a link between COPD and autoimmunity. Studies with clinical 
samples have demonstrated that autoantibodies are present in sera of COPD patients 
and some of these antibodies correlate with specific disease phenotypes. Furthermore, 
evidence from animal models of COPD has shown that autoimmunity against pulmonary 
antigens occur during disease development and is capable of mediating COPD-like 
symptoms. The idea that autoimmunity could contribute to the development of COPD 
provides a new angle to understand the pathogenesis of the disease. In this review 
article, we provide an advanced overview in this field and critically discuss the role of 
autoantibodies in the pathogenesis of COPD.
Keywords: autoimmunity, autoantibodies, chronic obstructive pulmonary disease, biomarkers, emphysema, 
experimental models, pathogenesis
inTRODUCTiOn
Chronic obstructive pulmonary disease (COPD) is a major public health problem affecting more than 
200 million people worldwide and leading to millions of death annually (1). COPD patients suffer 
from a progressive and not fully reversible airflow limitation. Pathologically, COPD is characterized 
by persistent pulmonary inflammation, obstruction of the small airways (obstructive bronchiolitis) 
and structural changes of the airways (emphysema) (2). It is widely accepted that COPD is triggered 
by inhaled toxic gases and particles. However, the pathogenesis of COPD remains largely unclear 
(2, 3).
Cigarette smoking (CS) is the major etiologic and risk factor for COPD (4, 5), and smoking 
cessation is beneficial for patients in terms of lung function (6). However, smoke cessation does 
not attenuate the pulmonary inflammation once COPD is established in patients (7, 8). The persis-
tence of the pulmonary inflammation after smoking cessation and the presence of well-organized 
lymphoid follicles around small airways and lung parenchyma of COPD patients (9–11) implicate 
that there are memory adaptive immune responses to non-cigarette antigens, such as autoantigens, 
commensal microbiota, and infectious pathogens (8, 12, 13). Among these candidates, autoantigens 
are of specific interest because both clinical and experimental evidence suggest that CS is capable 
of triggering autoimmunity. Thus, the exploration of the contribution of autoimmune responses 
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to the development of COPD could provide a new angle for 
understanding the pathogenesis of this disease.
In 2002, Cosio et  al. proposed a novel concept that COPD 
could be considered as an autoimmune disease triggered by 
smoking (14). In 2007, Lee et  al. reported that emphysema is 
characterized by the presence of humoral and cellular autoim-
mune responses against elastin, an extracellular protein impor-
tant for lung integrity (12), for the first time showing evidence for 
a role of autoimmunity in COPD pathogenesis. Thereafter, many 
efforts have been made to determine the role of autoimmunity 
in the development of COPD by the use of clinical samples and 
animal models. In this review article, we aim to summarize recent 
advances in this field, discuss the contribution of autoimmunity 
to COPD, and outline prospects for future research. Since the 
role of self-reactive T cells in COPD has been reviewed elsewhere 
(14–16), we focus here on autoantibodies in COPD and its animal 
models.
AUTOAnTiBODieS in COPD PATienTS
Presence of Autoantibodies in COPD
According to their targets, studies investigating the presence of 
autoantibodies in COPD can be roughly categorized into two 
groups, those addressing autoantibodies against undefined and 
those addressing defined antigens (Table 1).
The first group consists of studies in which autoantibodies 
against undefined autoantigens, such as tissues or cells were 
investigated. Given that the majority of autoantigens in COPD 
is probably unknown, determination of autoantibodies against 
lung tissue or its major cell types, e.g., epithelial or endothelial 
cells provides a proof-of-principle evidence for the presence of 
autoantibodies in this disease. In 2008, Feghali-Bostwick and col-
leagues detected IgG deposition within alveolar septa and small 
airway walls by immunohistochemical staining in six out of six 
of patients with severe COPD, but in none of six controls (17) 
indicating for the first time that anti-tissue antibodies are present 
in COPD patients. Such anti-tissue antibodies in COPD were also 
described in another study using indirect immunohistochemical 
staining in which Packard et  al. showed that IgG from COPD 
patients have a higher binding capability to non-smoker lung 
tissue section than IgG from healthy smokers (18). In addition, 
anti-tissue antibodies in COPD could also be detected using 
rodent tissues as antigen (19) confirming the presence of anti-
tissue antibodies.
Aside from studying anti-tissue autoantibodies, Feghali-
Bostwick et  al. went on to investigate autoantibodies more 
specifically directed against epithelial and endothelial cells (17). 
Their results showed that the prevalence of autoantibodies against 
epithelial cells, including both hepatoma (HEp-2) cell and pri-
mary pulmonary artery epithelial cells, is significantly higher in 
COPD patients as compared with smoker or non-smoker (17). 
In addition, 50% of the COPD patients are also characterized by 
autoantibodies against primary pulmonary artery endothelial 
cells (17). This study shows for the first time the presence of 
anti-epithelial and anti-endothelial autoantibodies in COPD 
patients. By using a cell-based enzyme-linked immunosorbent 
assay with human umbilical vein endothelial cells (HUVECs) 
as coated antigen, two independent research groups confirmed 
the presence of anti-endothelial IgG in COPD patients (20, 21). 
Recently, the presence of anti-epithelial IgG has also been shown 
in a study using human bronchial epithelial cells as target (22). 
Taken together, these studies demonstrate convincingly that 
autoantibodies against lung tissue as well as pulmonary epithelial 
and endothelial cells are detectable in patients with COPD.
In the second group of studies, autoantibodies against defined 
antigens suspected to be present in or functionally related to 
the disease were investigated. This group includes extracellular 
matrix (ECM) proteins, cellular proteins from pulmonary cells, 
neo-autoantigens, immune molecules, and autoantigens in com-
mon autoimmune diseases.
The main function of cellular matrix proteins is to maintain the 
structure and integrity of the lung. Since degradation of matrix 
proteins is a hallmark of emphysema, these proteins are promis-
ing candidates for autoantigens in COPD. As mentioned earlier, 
autoantibodies against elastin have been detected in emphysema 
patients, showing for the first time the presence of autoantibodies 
in COPD (12). However, beside one exception (18), all follow-
ing studies failed to confirm levels of anti-elastin antibodies in 
COPD patients surmounting those of healthy controls (23–26). 
Moreover, results from two independent groups showed that 
levels of anti-elastin antibodies are even lower in COPD patients 
than in healthy controls (27, 28). Beside elastin, collagens have 
been also extensively investigated as candidate autoantigens for 
COPD. Using an autoantigen array with 70 proteins, Packard 
and colleagues showed that levels of autoantibodies reactive to a 
broad spectrum of self-antigens are significantly higher in COPD 
patients involving emphysema than in healthy controls, including 
autoantibodies against collagen I, collagen II, and collagen IV 
(18). However, similar to the findings for anti-elastase antibod-
ies, these results were not confirmed by other groups (12, 23, 
25), keeping this issue under debate. Moreover, autoantibodies 
against aggrecan, another ECM protein, have been detected in 
patients with COPD (18).
In addition to ECM proteins, cellular proteins from pulmonary 
cells have also been regarded as potential autoantigens in COPD. 
Using immunoblotting assays with lysates prepared from alveolar 
cells as targets, Kuo et  al. showed that autoantibodies against 
multiple cellular antigens are more frequently present in sera of 
COPD patients than in controls (29). Among those antigens, a 
45-kDa cellular protein was identified as cytokeratin 18 (CK-18), 
an intermediate filament protein located in the intracytoplasmic 
cytoskeleton of epithelial tissue. Although this interesting finding 
has not been observed in a report based on a small number of 
samples (25), it has been confirmed in a recent study where 228 
COPD patients and 136 controls were included (30). Here, Xiong 
et al. could show that the levels of circulating IgG, IgA, and IgM 
autoantibodies against CK-18 are elevated in COPD patients as 
compared with healthy controls (30). Furthermore, they also 
demonstrated that COPD patient express autoantibodies against 
another intermediate filament protein, CK-19, suggesting another 
cellular autoantigen for the diseases (30).
Neo-autoantigens are antigens expressed under specific patho-
physiological conditions and are not ubiquitously in our body 
(31). Well-known neo-autoantigens in autoimmune diseases 
TABle 1 | Summary of autoantibodies in COPD.
Autoantigen Method COPD vs control Association with disease 
parameters
Reference
Tissues and cells Tissue Rodent tissue IIF Increased ATS/ERS stage and DLCO (19)
Human lung tissue DIH Increased – (17)
Human lung tissue IIH Increased Emphysema (18)
Epithelial HEp-2 cells IIF Increased No (17)
primary PAEpC IIF Increased – (17)
HBEC IIF Increased GOLD stages (22)
Endothelial primary PAEdC IIF Increased – (17)
HUVEC ELISA Increased No (20)
HUVEC ELISA Increased – (21)
Defined 
autoantigens
ECM proteins Elastin ELISA Increased – (12)
PA Increased – (18)
ELISA No difference – (25)
ELISA No difference – (23)
ELISA No difference – (26)
ELISA No difference – (24)
ELISA Decreased Emphysema and GOLD stage (27)
ELISA Decreased – (28)
Collagen I PA Increased – (18)
ELISA No difference – (23)
ELISA No difference – (12)
ELISA Decreased – (25)
Collagen II PA Increased Emphysema (18)
ELISA No difference – (25)
Collagen IV PA Increased – (18)
ELISA No difference – (25)
Aggrecan PA Increased Emphysema (18)
Alveolar cellular proteins Cytokeratin 18 WB Increased FEV1(L) and FEV1 (% predicted) (29)
ELISA Increased GOLD stage (30)
ELISA No difference – (25)
Cytokeratin 19 ELISA Increased GOLD stage (30)
Immune molecules Soluble CD80 ELISA, WB Increased GOLD stage (38)
αB-crystallin ELISA Increased No association (37)
β2-Microglobulin PA Increased – (18)
Neo-autoantigen CCP ELISA Increased No association (35)
ELISA No difference – (33)
ELISA No difference – (34)
ELISA No difference – (28)
CFFCP ELISA Increased No association (34)
MCV ELISA No difference No association (28)
CMP ELISA Increased FEV1 (% predicted) and GOLD 
stages
(21)
Autoantigens in common 
autoimmune disease
Nuclear IIF Increased No association (19)
IIF Increased No association (39)
IIF No difference – (33)
IIF No difference – (26)
Cardiolipin, CENP-B, cytochrome 
C, DGPs, H1, H2A, H2B, histone, 
JO-1, La/SS-B, LC1, PL-12, 
PL-7, Ro52 (SSA), thyroglobulin, 
topoisomerase, snRNP-68, 
U1-snRNP-BB, and U1-snRNP-A
PA Increase Emphysema (18)
HEp-2 cells, hepatoma cell; primary PAEpC, primary pulmonary airway epithelial cells; HBEC, human bronchial epithelial cell; primary PAEdC, primary pulmonary artery endothelial 
cells; HUVEC, human umbilical vein endothelial cell; IIF, indirect immunofluorescence, DIH, direct immunohistochemistry; IIH, indirect immunohistochemistry; ELISA, enzyme-linked 
immunosorbent assay; WB, western blot; PA, protein array; ECM, extracellular matrix proteins; CCP, citrullinated peptides; CFFCP, chimeric citrullinated peptides of human fibrin 
and filaggrin; MCV, mutated citrullinated vimentin; DGPs, deamidated gliadin peptides; CMP, carbonyl-modified proteins; COPD, chronic obstructive pulmonary disease; ATS/ERS, 
American Thoracic Society/European Respiratory Society.
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such as rheumatoid arthritis (RA) are citrullinated peptides or 
proteins which are generated by a posttranslational modification 
process occurring under certain inflammatory conditions (32). 
Results from several studies using different citrullinated peptides 
or proteins as antigens have shown that the frequencies of sera 
with anti-citrullinated protein antibody (ACPA) are very low in 
both COPD patients and healthy controls and without significant 
difference between these two groups (33–35). When the concen-
trations of ACPA are used for comparison, levels of anti-cyclic 
citrullinated peptide antibodies (CCP2) have been shown to 
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be higher in sera of COPD patients than controls in one study 
(35), which was not confirmed by three other groups (28, 33, 
34). Carbonyl-modified proteins (CMP) represent another type 
of neo-autoantigen, which are investigated in COPD. Oxidants, 
a major constituent of cigarette smoke, can cause the formation 
of carbonyl adducts on proteins in vivo (36), making it conceiv-
able that autoantibodies against CMP are generated in COPD 
patients. To verify this hypothesis, Kirkham et  al. determined 
levels of autoantibodies against CMP in the sera of COPD 
patients and controls. They found that antibody titers against 
carbonyl-modified self-protein were significantly increased in 
patients with COPD as compared with controls (21) showing the 
presence of such autoantibodies.
Apart from molecules from cells residing in the lung, some 
molecules from immune cells have also been shown to act 
as autoantigens in COPD. In 2012, Cherneva and colleagues 
reported that concentrations of autoantibodies against αB-
crystallin (HspB5), a marker of innate immune activation, were 
increased in patients with COPD (37). Notably, according to 
this study, those autoantibodies are also present in inflamma-
tory lung diseases suggesting that they are not COPD specific. 
Very recently, Luo et  al. investigated autoantibodies against 
a soluble form of CD80 (sCD80), a co-stimulatory molecule 
for T cell activation, in sera of patients with COPD (38). They 
found that serum levels of anti-sCD80 were higher in patients 
with COPD than in controls and were positively correlated 
to inflammatory cytokines, e.g., IL-6 and IL-8 (38). Another 
immune molecule, β2-microglobulin that is a component of 
MHC class I molecules, has also been identified as an autoan-
tigen in COPD (18).
Finally, autoantigens that have already been described in some 
common autoimmune diseases have also been investigated in 
COPD. For example, using indirect immunofluorescence stain-
ing, two independent groups have demonstrated that antinuclear 
antibodies are more prevalent in patients with COPD than healthy 
controls (19, 39). Although this difference has not been found in 
two other studies using the same detection method (26, 33), a 
study using protein arrays carrying 70 different antigens has con-
firmed that sera of patients with emphysema have autoantibodies 
reactive to many common nuclear antigens (18). In this study, the 
reactivity of sera derived from patients suffering from systemic 
lupus erythematosus (SLE) and RA was analyzed in comparison. 
Interestingly, emphysema-associated COPD was characterized 
by a lower autoantibody reactivity than SLE, but a higher than 
RA (18), suggesting COPD is indeed associated with a substantial 
level of autoimmunity.
Taken together, a number of previous studies have demon-
strated that autoantibodies are present in patients with COPD. 
However, their determination and visualization appear to be 
autoantigen and method depending.
Does the Presence of Autoantibodies 
Correlate with Clinical Parameters in 
COPD?
Aside from demonstrating the mere presence of autoantibod-
ies, their potential correlation with disease parameters is 
important for their clinical relevance as biomarkers and could 
provide further evidence for a role of autoantibodies in COPD. 
Therefore, some studies with well characterized patients inves-
tigated the correlation between autoantibodies and clinical 
parameters of COPD.
By comparing subgroups of COPD patients categorized by 
clinical parameters, Nunez and colleagues demonstrated that 
the prevalence of anti-tissue antibodies are significantly different 
among patients groups with various disease severity as indicated by 
American Thoracic Society/European Respiratory Society (ATS/
ERS) stage or diffusing capacity of carbon monoxide (DLCO). 
Patients with more severe disease showed higher prevalence of 
anti-tissue antibodies (19), suggesting an association between 
the presence of anti-tissue antibodies and an increased disease 
severity. In another study, Packard and colleagues described that 
sera from COPD patients with emphysema showed a higher anti-
tissue antibody reactivity than sera from COPD patients without 
emphysema, suggesting an association of this autoantibody with 
emphysematous disease.
Recently, an association between severity of COPD and 
anti-epithelial antibodies has been demonstrated by Cheng 
et al. (22). They found that the prevalence of both anti-epithelial 
IgG and IgA are elevated in patients with severe disease (GOLD 
stage III or IV) as compared with patients with milder symp-
toms (GOLD stage I or II) (22). However, the association of 
anti-epithelial antibodies with disease severity has not been 
observed in a study with a rather small number of patients 
(17). Based on these inconsistent results from current studies, 
it remains unclear whether anti-epithelial antibodies are indeed 
associated with severity of COPD.
The correlation with clinical parameters of COPD has also 
been shown for autoantibodies directed against some defined 
antigens. For example, in Packard’s study, they found that serum 
levels of autoantibodies against many antigens are significantly 
higher than in COPD patients without emphysema (18). Disease 
severity is also reported to be associated with autoantibodies 
against several other antigens. In 2010, Kuo et al. reported that 
levels of autoantibodies against CK-18 were inversely correlated 
with lung function parameters (29). This correlation is confirmed 
by investigations of Xiong et  al. who showed that circulating 
levels of both anti-CK-18 and anti-CK-19 autoantibodies cor-
relate significantly with the severity of the disease (30). Besides 
anti-CK-18 and anti-CK-19, two other autoantibodies have been 
reported to correlate with disease severity in COPD. While the 
presence of anti-sCD80 antibodies was shown to be associated 
with a high GOLD stage (38), autoantibodies against CMP cor-
related with a high GOLD stage and were inversely correlated 
with lung function parameters (21).
Notably, anti-elastin antibodies are also associated with dis-
ease parameters, but in contrast to all autoantibodies mentioned 
earlier, in the opposite direction where a lower antibody titer was 
associated with more severe disease and emphysema (27).
AUTOAnTiBODieS in AniMAl MODelS 
OF COPD
Animal models are powerful research tools for investigating the 
pathogenesis of human diseases. For COPD, such models have 
TABle 2 | Autoantibodies in animal models of COPD.
Animal models Disease symptoms Autoantibodies Reference
CS-exposed mice Pulmonary 
inflammation with 
macrophages and 
B cells
Anti-ECM (41)
ECM-immunized mice Pulmonary 
inflammation with 
macrophages
Anti-ECM (41)
CS-exposed rat emphysema Anti- β2-AR (42)
β2-AR immunized rat Emphysema Anti- β2-AR (42)
HUVEC-immunized rat Emphysema Anti-HUVEC (44)
IgG transfer-induced 
rat
Emphysema Anti-HUVEC (44)
CS, cigarette smoking; ECM, extracellular matrix, β2-AR, β2-adrenergic receptor; 
HUVEC, human umbilical vein endothelial cell; COPD, chronic obstructive pulmonary 
disease.
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been established in many species, including mice, rat, dog, mon-
key, and guinea pig (40). In consistence with findings in COPD 
patients, evidence from animal models also supports a role of 
autoantibodies in the pathogenesis of COPD, especially in those 
with emphysema (Table 2).
In 2010, Brandsma and colleagues reported that chronic 
CS-exposure leads to the pulmonary inflammation and produc-
tion of autoantibodies against multiple ECM components in mice 
(41). To further explore the role of autoantibodies against ECM in 
this mouse model, the authors immunized mice with a mixture 
of lung ECM. As expected, mice immunized with ECM produced 
high levels of autoantibodies against different ECM components. 
In addition, the immunization alone increased the number of 
macrophage in the lung tissue suggesting a proinflammatory role 
of autoimmunity against ECM (41). Unfortunately, emphysema, 
which is associated with autoantibodies in human COPD, was not 
observed in their model disabling the evaluation of a potential 
association between autoimmunity against ECM and emphysema 
development (41). Very recently, a study investigating CS-induced 
rat model of COPD shed some new light on this field (42). In this 
study, Hu et  al. reported that CS-exposed rats produce higher 
levels of autoantibodies against β2-adrenergic receptors (β2-ARs) 
than control rats (42). Moreover, autoantibodies against β2-ARs 
are associated with severity of CS-induced emphysema suggest-
ing that the autoimmunity might be involved in the formation 
of emphysema. To confirm this notion, the authors immunized 
rats with the peptide of the second extracellular loop of β2-ARs 
which contains an epitope recognized by agnostic autoantibodies 
against β2-ARs (42, 43). Rat immunized with the β2-ARs peptide 
produces autoantibodies against β2-ARs and development of 
emphysema, confirming the role of autoimmunity against β2-ARs 
in pathogenesis of COPD-like disease (42). Therefore, evidence 
from CS-induced animal models demonstrates that CS-exposure 
triggers autoimmunity against multiple autoantigens in the lung 
and such autoimmunity contribute to COPD-like symptoms.
Beside CS-expose induced approaches, models induced 
by active immunization also provide evidence for a role 
of autoimmunity in the pathogenesis of COPD. In 2005, 
Taraseviciene-Stewart and colleagues reported a new animal 
model for COPD in rats (44). Rats immunized with HUVECs 
raised antibodies against HUVECs and developed emphysema. 
Interestingly, adoptive transfer of either serum or CD4+ T cells 
from the HUVECs-immunized rat into naive immunocompetent 
rats induced subsequent emphysema (44). These results suggest 
an autoimmune-driven mechanism beneath the disease manifes-
tation in experimental COPD which involves both autoreactive 
T cells and autoantibodies.
COnClUSiOn AnD PeRSPeCTiveS
In summary, the abovementioned clinical and experimental 
studies provide some evidence for the role of autoantibodies in 
COPD. First, autoantibodies are present in both COPD patients 
and in corresponding animal models, particularly those involv-
ing emphysema. This notion is supported by the finding that 
severe COPD with emphysema is associated with HLA II alleles 
which is associated with most autoimmune diseases (45). Second, 
correlation between autoantibodies and disease severity has been 
described but appears not to be consistent among different studies. 
Third, autoantibodies in animal models of COPD are capable of 
inducing a COPD-like disease phenotype. Those evidence, alone 
with the fact that COPD patients are characterized by increased 
numbers of B cells, plasma cells, and B cell-rich lymphoid follicles 
that correlate directly with disease severity (11, 46), support a 
role of autoantibodies in the development of COPD. Besides 
humoral autoimmunity, it is important to mention that cellular 
autoimmunity might also contribute to COPD pathogenesis. As 
aforementioned, human autoreactive CD8+ and CD4+ T  cells 
have been suggested to contribute to COPD (14–16). In addi-
tion, transfer of CD4+ T cells from the HUVECs-immunized rat 
is able to induce emphysema, supporting a role of autoreactive 
CD4+ T cells in experimental COPD (44).
With immunodeficient mice which lack both T- and B-cells, 
the role of adaptive immunity in experimental COPD can be 
explored. In 2010, Motz et  al. reported that transfer of T  cells 
from CS-exposed mice, but not T  cells from fresh air-exposed 
mice, into Rag2−/− mice led to the development of pulmonary 
inflammation and emphysema in the recipient mice (47), sug-
gesting that adaptive immune responses are capable to mediate 
COPD-like symptoms. However, by directly exposing immu-
nodeficient mice to CS, two research groups have demonstrated 
that immunodeficient mice develop comparable COPD-like 
disease as wild-type controls mice (48, 49), indicating that adap-
tive immune responses are not required for CS-induced COPD 
in mice. Since autoimmunity is a part of adaptive immune 
responses, the abovementioned experimental evidence suggests 
that autoimmunity is potentially pathogenic but dispensable for 
CS-induced COPD in animals. However, since human differ 
from animals in many aspects, findings from animal models 
might not sufficiently reflect human diseases. Therefore, whether 
autoimmunity is a pathogenic or an indispensable event in the 
development of COPD remains elucidative.
6Wen et al. Autoantibodies in COPD
Frontiers in Immunology | www.frontiersin.org January 2018 | Volume 9 | Article 66
In conclusion, previous studies have suggested a potential role of 
autoimmunity in COPD and its animal models, opening a new field 
for exploring the pathogenesis of the diseases. Further investigations 
in this field will not only help for understanding the pathogenesis of 
COPD but also help for both diagnostic and treatment of the disease.
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